|
|
|
| home > ebr > autumn 2020 > the numerous challenges of a rapidly developing sector |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
|
Farmers have manipulated agriculture and livestock for thousands of
years. It’s no surprise, then, that discovery and development are the
primary goal of each of the four biotechnology markets, including:
•
Bio-health: Bio-health companies are hyper-focused on the R&D
portion of the medical sector. These companies take significant risks to
design new drugs quicker and more effectively. Bio-health thrives
‘behind the scenes’, starting with foundational research to product
launch instead of marketing or sales
• Agri-biotech:
Ground-breaking agricultural advances have always played a vital role in
agri-biotech. For example, scientists successfully cloned the first
mammal in 1996 – a sheep named Dolly. Aside from animal cloning however,
agri-biotech pursues crop improvement by crop cloning, modifying genes,
and more. Many farmers thrive on transgenic and bioengineered crops,
too
• Bio-energy: The biotech industry solves
environmental problems by studying natural environments. The bio-energy
market studies microorganisms and works to create a more sustainable and
preserved world with less pollution
• Bioindustrial:
More than for medicine, food, or energy, biotech focuses on non-food
uses of crops and other products. The bioindustrial market can transform
unpalatable raw materials into edible food. Additionally, the biotech
industry’s advances have extended the shelf-life of many foods based on
innovative packaging and product storage
Navigating the Legal Climate of Biotech
Plenty
of legal issues surrounding the biotech industry are cause for concern
with those involved in the space. Furthermore, each legal layer, or
apprehension, indirectly contributes to the complexity of this market.
There are vulnerabilities abound, but players tend to weigh their
options differently than in any other industry.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETOT (pralsetinib)
Catalent, the leading global provider of advanced delivery technologies,
development, and manufacturing solutions for drugs, biologics, cell and
gene therapies, and consumer health products, today announced that it
had entered into a commercial supply agreement with Blueprint Medicines
following FDA approval of GAVRETO™ (pralsetinib). Developed by Blueprint
Medicines, GAVRETO is a new therapy indicated for the treatment of
adults with metastatic RET fusion-positive non-small cell lung cancer
(NSCLC) as detected by an FDA approved test.
More info >> |
|
 |
White Papers |
 |
|
Speciality Logistics Outlook 2015
World Courier
To date, there are more than 178,000 registered clinical trials taking place across the globe, and global pharma’s volume has more than doubled over the last decade. With emerging markets showing explosive predictive growth through 2016, shippers and trial sponsors can expect continued regulatory and overall logistics complexities that foster demand for local, inmarket resources across the globe.
More info >> |
|
 |
Industry Events |
 |
12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology
8-11 February 2021, Vienna, Austria
In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >> |
|
|
.jpg)
